VYKOURA

Launch

leucovorin calcium

NDAINTRAMUSCULAR, INTRAVENOUSSOLUTION
Approved
Feb 2026
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
6

Clinical Trials (5)

NCT04060017Phase 2Recruiting

Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium

Started Sep 2020
80 enrolled
Autism Spectrum DisorderLanguage Disorders
NCT03337087Phase 1/2Active Not Recruiting

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Started Nov 2018
18 enrolled
Metastatic Biliary Tract CarcinomaMetastatic Colorectal CarcinomaMetastatic Gastroesophageal Junction Adenocarcinoma+6 more
NCT01238965Phase 1Terminated

Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy

Started Oct 2010
7 enrolled
Recurrent Colon CancerRecurrent Rectal CancerStage IV Colon Cancer+1 more
NCT01150045Phase 3Unknown

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

Started Jun 2010
2,527 enrolled
Colorectal Cancer
NCT00942266Phase 2Completed

Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment

Started Jul 2009
58 enrolled
Adenocarcinoma of the ColonAdenocarcinoma of the RectumRecurrent Colon Cancer+3 more

Loss of Exclusivity

LOE Date
Dec 23, 2044
229 months away
Patent Expiry
Dec 23, 2044

Patent Records (1)

Patent #ExpiryTypeUse Code
12564592
Dec 23, 2044
Product